KemPharm Reports Q4 and FY 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Kempharm (KMPH) PT Lowered to $8 at Oppenheimer
March 1, 2019 9:30 AM ESTOppenheimer analyst Esther Rajavelu lowered the price target on Kempharm (NASDAQ: KMPH) to $8.00 (from $10.00) while maintaining a Outperform rating.
The analyst commented, "KMPH announced 4Q results and provided an update on the business. Management is focused on KP415/KP484 development, with a... More
